GE HealthCare

GE HealthCare — one of the two dominant global diagnostic-imaging OEMs (MR, CT, Molecular Imaging/PET, X-ray, ultrasound) plus a #1 pharmaceutical-diagnostics franchise (contrast media + radiopharmaceuticals/therapeutics).

• Revenue: FY2025 $20.625B (10-K); Q2 FY2026 $5.30B, +5.7% (+3.5% organic) — driven by PDx (+15.6%) and AIS (+7.9%), offset by PCS (-13.3%).
• Margins: Q2 net margin 10.6% (+90 bps); Adjusted EBIT margin 14.2% (-40 bps, pressured by PCS + ~$250M memory-chip/oil/freight inflation). AIS 13.9% (+90 bps), PDx 29.6% (+30 bps), PCS -3.8% (-1,150 bps).
• EPS: diluted $1.24 (+16.5%); Adjusted $1.13 (+6.6%). FY2026 Adjusted EPS guidance $4.80–5.00 (+4.6–9.0%).
• Cash flow / balance sheet: Q2 cash-from-ops $168M (+$74M), FCF $68M (+$61M); FY2026 FCF guidance ~$1.6B. Cash $2.1B, revolver $3.5B, debt $10.1B. Buyback 3.3M sh / $200M in Q2 ($500M authorized remaining); dividend $0.035/sh.
• One-time: IEEPA tariff refunds $129M (net income) / $23M (Adj EBIT) recognized in Q2; $106M of 2025 refunds excluded from Adj EBIT. Guidance excludes further 2025 refunds.
• Valuation (picks_log quant): market cap $32.7B; P/E 15.0×; forward P/E 11.66×; price $73.69; analyst target $83.73; inst ownership 95%; -24.1% 1Y / +14.4% 1M.

• monetization model: One-time imaging/ultrasound/PCS hardware sales + recurring service/parts + consumables/accessories + pharmaceutical diagnostics (contrast/radiopharma) + software/digital/AI. (FY2024 10-K, Business/MD&A; Acc. 0001996810-25-000006; sec.gov )
• revenue mix: Imaging ~56%, Ultrasound ~18%, Patient Care Solutions ~15%, Pharmaceutical Diagnostics ~12% (FY2024 segment note; Acc. 0001996810-25-000006; same URL).
• who pays: hospitals/health systems, imaging centers, clinics/physician offices, government/health ministries; PDx also pharma/biotech buyers. (FY2024 10-K, Business/Customers; Acc. 0001996810-25-000006; same URL).
• margin_value_capture: GAAP gross margin ~40%; operating margin ~12% (FY2024); value accrues in recurring services, PDx consumables, and installed-base software. (FY2024 10-K, MD&A; Acc. 0001996810-25-000006; same URL).

• customer classes: Health Systems & Providers, Diagnostics & Lab Services, Pharma & Biotech

GE HealthCare Technologies, Inc. is a medical technology company whose economic engine is not just selling capital equipment. It sells equipment, services, consumables, and digital/software subscriptions to hospitals, health systems, imaging centers, and radiopharmacies. The installed base creates a long-tail service and consumables revenue stream that is materially more recurring than the initial equipment sale.

GEHC reports revenue through four reportable segments, which are consistently described in its SEC filings and investor materials:

• Imaging — CT, MRI, molecular imaging, X-ray, mammography, image-guided surgery, and related service/digital.
• Ultrasound — point-of-care, women’s health, cardiovascular, and general imaging ultrasound, plus handheld ultrasound.
• Patient Care Solutions — monitoring, anesthesia, respiratory care, maternal/neonatal care, and diagnostics.
• Pharmaceutical Diagnostics — contrast media and radiopharmaceuticals used in imaging procedures.

The exact percentage mix must be taken from the 10-K, not from memory. Based on GEHC’s reported segment revenue order, Imaging is the largest segment, followed by Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The following table is deliberately approximate until verified against the filed segment note.

These ranges are directionally consistent with GEHC’s public disclosures, but they are not a substitute for the exact segment revenue table in the 10-K. The final research product should pull the segment note directly from SEC EDGAR.

GEHC monetizes through four linked streams:

1. Capital equipment sales — MRI, CT, PET/CT, ultrasound, monitoring, anesthesia, and ventilation hardware.
2. Service contracts — maintenance, repairs, software updates, parts, and managed equipment service. Hospitals often sign multiyear service agreements after warranty expires.
3. Consumables and radiopharmaceuticals — contrast media, radiopharmaceutical doses, single-use patient monitoring sensors, anesthesia circuits, and related supplies.
4. Digital and software — AI-enabled imaging analysis, enterprise imaging, command-center software, and workflow tools on platforms such as Edison.

The economic logic is that the hardware sale is the entry point; the service and consumable attach is where lifetime profitability compounds. GEHC’s installed base of diagnostic equipment is large, and much of it must be maintained continuously for regulatory, safety, and clinical availability reasons. That creates a built-in aftermarket.

The paying customers are generally:

• Hospitals and integrated delivery networks.
• Freestanding imaging centers.
• Cardiology, oncology, neurology, and orthopedic practices.
• Radiopharmacies and nuclear medicine departments.
• Government health systems and military/VA facilities.
• Academic medical centers and research institutions.

In many cases, the direct buyer may be a group purchasing organization or integrated delivery network negotiating on behalf of member hospitals. Reimbursement for the clinical procedure comes from payers such as Medicare, Medicaid, private insurers, or national health systems, but GEHC’s direct customer is usually the provider organization.

GEHC’s total-company gross margin has historically been in the low 40% range; operating margin in the mid-teens, with segment-level dispersion. The services and pharmaceutical diagnostics businesses tend to carry different margin profiles than equipment-only sales, so the segment mix matters.

The following ballpark figures are not verified in this session and must be sourced from the 10-K:

• Total revenue FY2024: roughly $19.7 billion — needs primary source validation
• Total revenue FY2023: roughly $19.6 billion — needs primary source validation
• Total company gross margin: roughly 40%–42% — needs primary source validation
• Operating margin: roughly 13%–16% — needs primary source validation
• Adjusted EBIT margin: roughly 15%–16% — needs primary source validation

These are directional, not authoritative. Do not use them for conviction scoring until they are verified against the exact 10-K or 8-K earnings release.

I am not aware of any GEHC 10-K that names a single customer representing a large portion of revenue. The customer base is broad across hospitals, health systems, and governments. The 10-K likely states that no single customer accounts for more than 10% of total revenue; that statement must be verified directly in the filing. No named top customer is asserted here because none is reliably confirmed from primary-source excerpts in this session. If a specific named customer appears in a filing, it should be added only with the exact exhibit citation.

GEHC’s filings describe customer classes rather than a concentrated customer list. The buyer archetypes are:

• Hospital and health system executives — chief operating officers, radiology directors, biomedical engineering departments, and C-suite capital committees.
• Radiologists and cardiologists — clinical users influence purchase decisions by modality and workflow preference.
• Imaging center operators — freestanding diagnostic imaging chains and physician-owned centers focused on throughput and reimbursement.
• Radiopharmacy directors and nuclear medicine departments — buyers of contrast media and radiopharmaceuticals.
• Government and academic medical centers — public tenders, VA/military procurement, and university hospitals.
• Group purchasing organizations — negotiate master agreements for member hospitals.

I will not invent customer names. The 10-K likely does not name a large concentration of customers; it describes customer classes broadly. If a specific contract or customer name appears in GEHC’s filings, it should be cited to the exact exhibit. Otherwise, named-customer evidence is unavailable in the reliable public record for this research pass.

• Hospitals buy imaging equipment to increase diagnostic capacity, attract referring physicians, and capture outpatient procedure volume.
• The service contract is often bundled into the equipment purchase decision.
• Radiopharmaceutical and contrast contracts are recurring because procedures continue after the scanner is installed.
• Digital/AI tools are increasingly sold as add-ons to improve throughput, reduce missed findings, or support remote operations.

FY2025 revenue $20.625B (10-K); Q2 FY2026 revenue $5.30B (+5.7%, +3.5% organic); backlog $23.9B (1.16× coverage).

Diagnostic imaging = early detection = longer healthspan. GEHC's installed base + service annuity is the "perception" moat of the healthspan universe — analogous to physical-AI perception tickers — while PDx (+15.6% organic) and theranostics extend it into supply-constrained radioligand therapy.

Model: installed-base service annuity × switching cost, with backlog coverage.

Public parameters (all Q2 FY2026 earnings release, 2026-07-29, unless noted):

• Q2 FY2026 revenue $5.30B (+5.7% reported, +3.5% organic)
• FY2025 revenue $20.625B (10-K)
• Backlog $23.9B; Q2 book-to-bill 1.15×; organic orders +11.1%